.
.-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018.
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
a sign at a planned parenthood clinic is pictured in oklahoma city, in 2015.
.
chat with us in facebook messenger. find out what's happening in the world as it unfolds.
.![]()
.
email